jcm-logo

Journal Browser

Journal Browser

Modern Blood Banking and Transfusion in Clinical Practice: Second Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 25 November 2025 | Viewed by 710

Special Issue Editor


E-Mail
Guest Editor
Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
Interests: blood transfusion; patient blood management; blood banking; immunohematology; cell therapy; transplantation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to the Special Issue “Modern Blood Banking and Transfusion in Clinical Practice: Second Edition”. This is a new edition; we published four papers in the first volume. For more details, please visit https://www.mdpi.com/journal/jcm/special_issues/Blood_Banking_Transfusion.

Blood banking and blood component transfusion practices have improved considerably over the years. Some of the notable changes are the increasing automatization of compatibility testing and the implementation of electronic systems to monitor the transfusion process to record adverse effects; however, in the last decade blood banks have faced new problems. The use of monoclonal antibodies, such as anti-CD38 and anti-CD47, for the treatment of patients with malignancies is a concern, since these treatments produce interference with pretransfusion compatibility tests, delaying blood availability. In addition, the infusion of cell therapy products is carried out by blood bank staff in many countries. Therefore, blood banks must be on alert to provide a response to these new challenges in a timely manner.

Transfusion is one of the most widely used therapies, sometimes involving inappropriate episodes. Benefits and risks have to be carefully considered in each clinical situation when a blood transfusion is requested. Over the last decade hemovigilance systems have detected a decline in red blood cell usage, which could be explained in part by the incorporation of restrictive strategies based on current scientific evidence. In fact, patient blood management programs are being progressively incorporated into clinical practice in order to reduce unnecessary blood exposure and improve patient outcomes.

The aim of this Special Issue is to provide updates on the most relevant advances in blood banking laboratory and transfusion practise, focusing on those situations in which transfusion can be  challenging, such as sickle cell disease, solid organ transplantation, massive transfusion, and cell therapy recipients, among others.

Dr. Pilar Solves
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood transfusion therapy
  • patient blood management
  • restrictive transfusion
  • cell therapy
  • platelet transfusion

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 215 KB  
Article
Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center
by Lara Eritzpokhoff, Ernesto Talegón De La Fuente, Aida Carril Barcia, Pedro Asensi Cantó, Ines Gómez Segui, Mario Arnao Herraiz, Javier De La Rubia Comos and Pilar Solves Alcaina
J. Clin. Med. 2025, 14(16), 5754; https://doi.org/10.3390/jcm14165754 - 14 Aug 2025
Viewed by 307
Abstract
Background/Objectived: Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of multiple myeloma. Its use interferes with the indirect antiglobulin test (IAT). Treatment of reagent red blood cells (RBCs) with dithiothreitol (DTT) is one of the most validated techniques to resolve this [...] Read more.
Background/Objectived: Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of multiple myeloma. Its use interferes with the indirect antiglobulin test (IAT). Treatment of reagent red blood cells (RBCs) with dithiothreitol (DTT) is one of the most validated techniques to resolve this interference. The objective of this study is to evaluate the rate of alloimmunization in transfused patients receiving daratumumab and the occurrence of hemolytic transfusion reactions. Materials and Methods: We conducted a single-center, retrospective, descriptive analysis of all patients treated with daratumumab at our institution from October 2016 to April 2024. For daratumumab-treated patients requiring RBC transfusions, an IAT with DTT-pretreated RBCs (DTT-IAT) was performed using the automated Orthovision system. Transfusion was administered only with a previous negative DTT-IAT while respecting Rh and Kell phenotyping. We assessed the transfusion profile of our patient cohort, including their rates of alloimmunization before and after daratumumab initiation, as well as the incidence of hemolytic complications. Additionally, a literature review was performed on reported alloimmunization rates in daratumumab-treated patients. Results: Among all patients, 106 received RBC and/or platelet transfusions after starting daratumumab. Four had known pre-existing alloantibodies. None developed new alloantibodies or experienced hemolytic complications while receiving anti-CD38 therapy. There were four cases of false-positive DTT-IAT due to residual drug interference or technical variability, in which no alloantibodies or adverse transfusion reactions were detected. Conclusions: Patients receiving daratumumab exhibit a low risk of alloimmunization. This may be partly explained by adherence to Rh and Kell phenotyping and daratumumab’s immunosuppressive effects on alloantibody production. These results support the conclusion that an extended red blood cell phenotype or genotype before starting daratumumab could be omitted if a fast and reliable technique for pretransfusion testing (such as automated DTT-IAT) is available 24 h. Full article
Back to TopTop